Although the efficacy of HIF-PH inhibitors in patients with chronic heart failure and renal anemia has not yet been clearly demonstrated, improvements in Hb levels may be an effective approach to evaluate the effects of these drugs in cardiorenal anemia syndrome. The gene discussed is GSTM1; the disease is congestive heart failure.